Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research

R L Hayward, J M Dixon

Research output: Contribution to journalArticlepeer-review

Abstract

Adjuvant endocrine therapy following surgical resection of early, endocrine sensitive breast cancer has proven benefits in reducing risk of recurrence and death, as demonstrated in many mature well controlled clinical trials. The introduction of new endocrine therapies as potential alternatives to tamoxifen or ovarian ablation and the incorporation of neoadjuvant endocrine therapy into the overall management strategy continue to provide exciting challenges for clinical research. In this article the focus is on as yet unanswered questions pertinent to adjuvant or neoadjuvant endocrine therapy for breast cancer. In the process, we broadly outline the current limits of knowledge as we understand it. Many relevant and current clinical trials are ongoing and a list of these with contact details or references are provided. Definitive data is urgently needed in many areas and, when available, will provide important evidence on which the management of breast cancer patients in future can be based. Participation in relevant clinical trials is vital for future progress.
Original languageEnglish
Pages (from-to)289-304
Number of pages16
JournalSurgical Oncology
Volume12
Issue number4
DOIs
Publication statusPublished - Dec 2003

Keywords

  • Adult
  • Age Factors
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Estrogen Receptor Modulators
  • Female
  • Humans
  • Mastectomy
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Postmenopause
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Survival Analysis
  • Tamoxifen
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research'. Together they form a unique fingerprint.

Cite this